A detailed history of High Tower Advisors, LLC transactions in In8 Bio, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 10,000 shares of INAB stock, worth $2,500. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 10,000 -0.0%
Holding current value
$2,500
Previous $8,000 75.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.85 - $1.68 $8,500 - $16,800
10,000 New
10,000 $8,000
Q4 2022

Feb 08, 2023

SELL
$1.39 - $2.47 $5,787 - $10,285
-4,164 Reduced 29.4%
10,000 $23,000
Q3 2022

Nov 09, 2022

BUY
$1.77 - $2.89 $25,070 - $40,933
14,164 New
14,164 $28,000
Q2 2022

Aug 10, 2022

SELL
$2.02 - $4.68 $28,611 - $66,287
-14,164 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$2.76 - $4.6 $11,492 - $19,154
4,164 Added 41.64%
14,164 $47,000
Q4 2021

Feb 10, 2022

BUY
$4.39 - $8.55 $43,900 - $85,500
10,000 New
10,000 $44,000

Others Institutions Holding INAB

About IN8BIO, INC.


  • Ticker INAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,502,200
  • Market Cap $6.13M
  • Description
  • IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...
More about INAB
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.